IBN Announces Latest Episode of The Stock2Me Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.

LOS ANGELES, Dec. 13, 2022 (GLOBE NEWSWIRE) — via InvestorWire – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Stock2Me Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me’s latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In this podcast episode, Reichman introduced the history of BiondVax leading up to his appointment as CEO before discussing the company’s recent development efforts focused on innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets.

“BiondVax is a biotechnology company focused on research and development. It is located in Jerusalem, Israel. It was founded about 17 years ago by an entrepreneur who took a spinoff from the Weizmann Institute of Science in Israel with a mission to develop a universal influenza vaccine,” Reichman said. “The vaccine was developed in the laboratory of Professor Ruth Arnon, a world-renowned professor and researcher mostly known for co-developing Copaxone, the multiple sclerosis drug marketed by Teva Pharmaceuticals. The universal influenza vaccine was then developed by BiondVax throughout the next 15 years, covering Preclinical, Phase I and multiple Phase II trials before ending up with a Phase III – the biggest Phase III ever conducted by an Israeli pharma company, with 12,400 participants spanning seven countries.

“In October 2020, the company published its results from this pivotal Phase III trial and, unfortunately, the vaccine drug candidate showed that it did not meet its primary endpoint of showing good protection across seasons in influenza. At that point, the company went into distress, and I was called to join BiondVax as CEO… We restructured the company with a new mission and a new vision. In February 2021, we raised $12.8 million and, with the proceeds, hired a consulting firm that helped us think through the next steps for the company – which products we should in-license, what kind of technologies we should bring in-house and how we should develop the new BiondVax.

“[While attempting to develop the universal influenza vaccine], BiondVax built a state-of-the-art facility in Jerusalem. It’s a manufacturing facility that includes almost all of the steps of biological production… What we didn’t have at the time that I joined was the IP… We ended up contracting with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen. With these two institutes, we entered three contracts. One is an exclusive license for development and commercialization of a self-inhaled COVID-19 therapeutic. The second was an accompanying research collaboration agreement… The third contract was a five-year strategic research collaboration contract with these two institutes for the discovery and development of nanobodies for the treatment of additional diseases such as psoriasis, psoriatic arthritis, asthma and macular degeneration.”

Join IBN’s Stuart Smith and Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), to learn more about the company’s recent development efforts relating to its lead candidate, a self-administered inhaled COVID-19 NanoAb therapy, including its recent release of successful results from a preclinical in vivo proof-of-concept study.

To hear the whole podcast and subscribe for future episodes, visit https://podcast.stock2me.com.

The latest installment of The Stock2Me Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About BiondVax

BiondVax Pharmaceuticals Ltd. is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline. For more information, visit the company’s website at www.BiondVax.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]